CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,328,917 | -89.2% | 82,747 | -87.7% | 0.22% | -91.6% |
| Q4 2022 | $12,291,085 | -0.1% | 671,644 | +7.2% | 2.64% | +54.4% |
| Q3 2022 | $12,305,000 | +12.4% | 626,552 | +6.8% | 1.71% | +45.9% |
| Q2 2022 | $10,944,000 | -4.5% | 586,820 | +12.4% | 1.17% | -27.7% |
| Q1 2022 | $11,457,000 | -4.7% | 521,947 | +23.3% | 1.62% | +22.5% |
| Q4 2021 | $12,024,000 | +4.1% | 423,248 | -22.9% | 1.32% | +36.3% |
| Q3 2021 | $11,549,000 | -3.4% | 548,643 | -13.5% | 0.97% | +20.0% |
| Q2 2021 | $11,953,000 | +175.2% | 634,088 | +123.1% | 0.81% | +142.6% |
| Q1 2021 | $4,343,000 | – | 284,224 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |